Background We undertook a prospective systematic overview based on data from individual
patients from five long-term randomised trials that assessed inhibitors of angiotensin …

Summary Background Glucagon-like peptide-1 (GLP-1) receptor agonists differ in their
structure and duration of action and have been studied in trials of varying sizes and with …

The prevalence of conduction disturbances, particularly left bundle branch block (LBBB), is
strongly correlated with age and with the presence of cardiovascular disease. LBBB has …

The task of developing ESC Guidelines covers not only the integration of the most recent
research, but also the creation of educational tools and implementation programmes for the …

Background In patients with type 2 diabetes, inhibitors of sodium–glucose cotransporter 2
(SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose …

Background The benefit of an implantable cardioverter–defibrillator (ICD) in patients with
symptomatic systolic heart failure caused by coronary artery disease has been well …

Background Cardiovascular morbidity and mortality are higher among patients with type 2
diabetes, particularly those with concomitant cardiovascular diseases, than in most other …

Background Angiotensin-converting–enzyme (ACE) inhibitors such as captopril reduce
mortality and cardiovascular morbidity among patients with myocardial infarction …

Background Unconscious survivors of out-of-hospital cardiac arrest have a high risk of death
or poor neurologic function. Therapeutic hypothermia is recommended by international …

Background Treatment with angiotensin-converting–enzyme (ACE) inhibitors reduces
mortality among survivors of acute myocardial infarction, but whether to use ACE inhibitors …